Annovis Bio (ANVS) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ANVS Stock Alerts $11.86 -0.17 (-1.41%) (As of 03/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAnnovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data Cleaningmsn.com - March 24 at 7:05 PMAnnovis Bio (NYSE:ANVS) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - March 23 at 1:46 AMAnnovis Bio (NYSE:ANVS) Rating Reiterated by HC Wainwrightmarketbeat.com - March 21 at 8:38 AMAnnovis Bio Shares Up 31% on Progress Toward Reporting Data From Alzheimer's Studymarketwatch.com - March 21 at 7:57 AMAnnovis Bio Completes Data Cleaning for Buntanetap Studymarketwatch.com - March 20 at 9:49 PMANVS Jul 2024 30.000 callfinance.yahoo.com - March 20 at 4:49 PMAnnovis to release efficacy data on Alzheimer's drug in Aprilmsn.com - March 20 at 4:49 PMAnnovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Diseaseglobenewswire.com - March 20 at 7:30 AMANVS Oct 2024 5.000 putfinance.yahoo.com - March 18 at 9:13 PMShort Interest in Annovis Bio, Inc. (NYSE:ANVS) Increases By 7.3%marketbeat.com - March 18 at 7:27 PMANVS Apr 2024 20.000 callfinance.yahoo.com - March 18 at 10:25 AMAre Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?msn.com - March 18 at 10:25 AM$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year247wallst.com - March 15 at 9:11 AMAdage Capital Partners GP L.L.C. Acquires Shares of 300,000 Annovis Bio, Inc. (NYSE:ANVS)marketbeat.com - March 11 at 6:42 AMSell Signal: 3 Stocks to Unload Before the Bubble Burstsinvestorplace.com - March 6 at 3:33 PMAnnovis Bio to Shed Light on Neurodegenerative Diseases at International Conferencemsn.com - March 4 at 12:34 AMAnnovis Bio Announces Participation in Forum Discussion at AD/PD(TM) 2024stockhouse.com - February 29 at 7:00 PMBrookline Capital Downgrades Annovis Bio (ANVS)msn.com - February 28 at 8:13 PMMaintaining Hold on Annovis Bio Amid Phase 3 Parkinson’s Trial Concerns and Financial Uncertaintiesmarkets.businessinsider.com - February 28 at 3:12 PMAnnovis Bio falls after Brookline Capital downgrades on PD trial complicationsmsn.com - February 28 at 3:12 PMBrookline Capital Management Reaffirms "Hold" Rating for Annovis Bio (NYSE:ANVS)marketbeat.com - February 28 at 8:20 AMAnnovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024globenewswire.com - February 27 at 8:00 AMAnnovis Bio Inc (ANVS)investing.com - February 17 at 9:31 AMAIGH Capital Management LLC Sells 370,129 Shares of Annovis Bio, Inc. (NYSE:ANVS)marketbeat.com - February 16 at 12:28 PMAnnovis Bio Wraps Up Phase II/III Trial for Alzheimer's Drug Buntanetapmsn.com - February 16 at 8:32 AMBuy Rating Justified for Annovis Bio Amidst Promising Buntanetap Clinical Trials and Strong Commercial Prospectsmarkets.businessinsider.com - February 16 at 3:32 AMAnnovis Bio Inc.: Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Diseasefinanznachrichten.de - February 15 at 5:30 PMAnalysts Are Bullish on These Healthcare Stocks: Annovis Bio (ANVS), Alnylam Pharma (ALNY)markets.businessinsider.com - February 15 at 5:30 PMBuy Rating on Annovis Bio Amid Anticipated Positive Outcomes for Buntanetap in AD and PD Trialsmarkets.businessinsider.com - February 15 at 12:29 PMAnnovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Diseaseglobenewswire.com - February 14 at 7:30 AMOptimistic Outlook for Annovis Bio with Buy Rating Amid Promising Clinical Trialsmarkets.businessinsider.com - January 29 at 6:26 PMAnnovis Bio delays release of late-stage study results for experimental Parkinson's disease treatmentbizjournals.com - January 25 at 9:23 PMAnnovis Bio Inc.: Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcementfinanznachrichten.de - January 24 at 3:57 PMAnnovis falls 16% on Phase 3 data delay for Parkinson's drugmsn.com - January 24 at 3:57 PMWhy Annovis Bio (ANVS) Stock Is Getting Hammeredmsn.com - January 24 at 3:57 PMAnnovis Bio Shares Retreat 13% on Delay of Parkinson's Treatment Study Datamarketwatch.com - January 24 at 10:57 AMAnnovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponedmarkets.businessinsider.com - January 24 at 10:57 AMAnnovis Bio's Options: A Look at What the Big Money is Thinkingbenzinga.com - January 18 at 1:27 PMShort Interest in Annovis Bio, Inc. (NYSE:ANVS) Expands By 21.2%marketbeat.com - January 2 at 7:44 PMCanaccord Genuity Initiates Coverage of Annovis Bio (ANVS) with Buy Recommendationmsn.com - December 29 at 6:30 PMShort Interest in Annovis Bio, Inc. (NYSE:ANVS) Expands By 8.9%marketbeat.com - December 16 at 9:29 PMAnnovis Bio Inc Ordinary Shares ANVSmorningstar.com - December 15 at 8:15 AMAnnovis Bio Inc Ordinary Sharesmorningstar.com - December 12 at 10:28 PMAnnovis Bio to Participate in the 139th Yale CEO Summitfinance.yahoo.com - December 11 at 3:26 PMBuy Rating Affirmed for Annovis Bio Amid Clinical Success and Market Confidencemarkets.businessinsider.com - December 7 at 9:54 AMBuy Rating Affirmed for Annovis Bio Amidst Strong Clinical Trial Progress and Robust Financial Positionmarkets.businessinsider.com - November 30 at 9:19 AMPositive Outlook on Annovis Bio’s Alzheimer’s Trial Progress and Financial Valuation Supports Buy Ratingmarkets.businessinsider.com - November 29 at 8:40 AMAnnovis Bio Shares Rise 13% After Full Enrollment Reached for Buntanetap Studymarketwatch.com - November 27 at 5:08 PMAnnovis Bio gains after enrollment update on trial for Alzheimer’s drugmsn.com - November 27 at 5:08 PMAnnovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projectionsbenzinga.com - November 27 at 9:27 AM Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now ANVS Media Mentions By Week ANVS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANVS News Sentiment▼0.230.60▲Average Medical News Sentiment ANVS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANVS Articles This Week▼32▲ANVS Articles Average Week Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sagimet Biosciences News Today Spero Therapeutics News Today Assertio News Today Equillium News Today ProPhase Labs News Today Corvus Pharmaceuticals News Today Vaccitech News Today Carisma Therapeutics News Today Vaxxinity News Today Barinthus Biotherapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANVS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.